このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CYBERDYNE マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Yoshiyuki Sankai

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	18.3yrs
CEOの所有権	38.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	14.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Yoshiyuki Sankai (66 yo)

18.3yrs

在職期間

Dr. Yoshiyuki Sankai has been the President and Chief Executive Officer of CYBERDYNE Inc. since February 2006 and also serves as its Chairman. Dr. Sankai established CYBERDYNE, Inc. in June 2004. He has be...

取締役

名称	ポジション	在職期間	報酬	所有権
Yoshiyuki Sankai	Chairman	20yrs	データなし	38.24% ¥ 17.1b
Shinji Honda	Executive Director & COO	less than a year	データなし	データなし
Shinji Uga	Head of Corporate Department & Director	15.3yrs	データなし	データなし
Cees Vellekoop	Outside Audit & Supervisory Board Member	17yrs	データなし	データなし
Hikari Imai	Independent Outside Director	9yrs	データなし	データなし
Kenichiro Okamura	Independent Outside Audit & Supervisory Board Member	13yrs	データなし	データなし
Hiroaki Kawamoto	Director	20yrs	データなし	データなし
Yutaka Fujitani	Independent Outside Audit & Supervisory Board Member	13yrs	データなし	データなし
Akira Matsumura	Independent Outside Director	no data	データなし	0.0024% ¥ 1.1m

14.2yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: 7779の取締役会は経験豊富で経験豊富です ( 14.2年の平均在任期間)。

CYBERDYNE マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2026

CYBERDYNE Inc. to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings: EPS and revenues miss analyst expectations

U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy

U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy

Price target decreased by 21% to JP¥320

CYBERDYNE Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings released: JP¥1.65 loss per share (vs JP¥0.93 loss in 3Q 2023)

CYBERDYNE Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 463%, revenue upgraded

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: JP¥4.42 loss per share (vs JP¥0.13 profit in 2Q 2023)

CYBERDYNE Inc. to Report Q2, 2024 Results on Nov 14, 2023

CYBERDYNE Inc. to Report First Half, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: EPS: JP¥1.56 (vs JP¥1.12 in 1Q 2023)

New minor risk - Share price stability

CYBERDYNE Inc. to Report Q1, 2024 Results on Aug 14, 2023

Consensus EPS estimates fall by 783%

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast breakeven date moved forward to 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 449%, revenue upgraded

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

CYBERDYNE Inc. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥0.93 loss per share (vs JP¥0.74 loss in 3Q 2022)

CYBERDYNE Inc. to Report Q3, 2023 Results on Feb 14, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Consensus EPS estimates increase by 353%

Price target decreased to JP¥560

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to JP¥780

CYBERDYNE Inc. to Report First Half, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥1.28 loss in 1Q 2022)

CYBERDYNE Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Forecast breakeven date pushed back to 2024

Price target increased to JP¥810

Less than half of directors are independent

Now 23% undervalued after recent price drop

Price target increased to JP¥843

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CYBERDYNE Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Forecast breakeven date pushed back to 2023

Price target decreased to JP¥745

Second quarter 2022 earnings released: JP¥0.70 loss per share (vs JP¥1.38 profit in 2Q 2021)

CYBERDYNE Inc. Announces Medical HAL Single Joint Type Receives Medical Device Approval from Australian Therapeutic Goods Administration, Department of Health

CYBERDYNE Inc. (TSE:7779) acquired C2,Inc.

First quarter 2022 earnings released: JP¥1.28 loss per share (vs JP¥0.60 loss in 1Q 2021)

Cyberdyne Inc. Preliminary Results of Medical Hal Lower Limb Type Stroke Clinical Trial

Price target decreased to JP¥845

Full year 2021 earnings released: JP¥0.27 loss per share (vs JP¥0.71 loss in FY 2020)

New 90-day low: JP¥611

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd

Third quarter 2021 earnings released: JP¥0.40 loss per share (vs JP¥0.46 profit in 3Q 2020)

Revenue and earnings miss expectations

Analysts lower EPS estimates to -JP¥1.36

New 90-day low: JP¥644

CYBERDYNE Inc. to Report Q3, 2021 Results on Feb 12, 2021

CYBERDYNE Inc. Medical Hal Obtains Approval from Singapore Health Science Authority

CYBERDYNE Inc. Announces that Stroke Clinical Trial on Medical HAL is Complete

Price target raised to JP¥1,075

マネジメント基準チェック /14